GlassScriptPhysician profile
Jin-Hong Park
NPI 1225033038
$3,668.11
in general payments reported to CMS, 2019-2025
29 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $255 · 2021: $141 · 2022: $373 · 2023: $884 · 2024: $639 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Education: $20.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.57 |
| Education | $20.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $986.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.14 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $244.62 | 2019-2024 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $223.98 | 2019-2022 | |
| Janssen Biotech, INC. | $178.79 | 2022-2024 | Stelara, Remicade, Simponi |
| Celgene Corporation | $158.05 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $128.30 | 2024-2025 | Iqirvo |
| Cochlear Americas | $104.17 | 2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Daiichi Sankyo INC. | $91.89 | 2019-2020 | |
| Lilly USA, LLC | $88.63 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $87.77 | 2024-2025 | Resmetirom, Rezdiffra |
| Pfizer INC. | $83.99 | 2019-2024 | |
| Celltrion USA INC. | $81.66 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $77.70 | 2021 | |
| Phathom Pharmaceuticals, INC. | $58.90 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $57.96 | 2025 | Sucraid |
| Ardelyx, INC. | $54.78 | 2024-2025 | Ibsrela |
| Allergan, INC. | $49.79 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $40.77 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $38.34 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.44 | 2019-2021 | |
| Braintree Laboratories, INC. | $27.84 | 2023 | Sutab |
| Genzyme Corporation | $26.19 | 2024 | |
| Amgen INC. | $24.77 | 2022 | |
| Ethicon US, LLC | $20.33 | 2024 | Linx Reflux Management System |
| Medtronic, INC. | $18.44 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.35 | 2025 | Suflave |
| Alfasigma USA, INC. | $14.97 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin-Hong Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.